Mosaic Technologies has been acquired by Apogent Discoveries in 2000 Mosaic Technologies, Inc. develops proprietary and innovative molecular biology technologies that have a wide range of applications in clinical diagnostics, research and healthcare. The companys first two products, Acrydite Chemistry and Bridge Amplification Technology began generating sales and licensing revenues in 1998 when Operon Technologies and Research Genetics, Inc. began incorporating Acrydite-based probes into several of their products; and Affymax Technologies, a wholly owned subsidiary of Glaxo Wellcome, signed a licensing agreement for Bridge Amplification Technology. Mosaics first diagnostic product is being developed in collaboration with the Red Cross. The Hybriscan System, which is scheduled for clinical trials in late 1999, will enable blood banks to cost effectively test donated platelets, prior to transfusion, for the presence of potentially deadly bacterial contamination. The system detects 1,000 bacteria in 1 mL of blood, in less than 30 minutes, and for under $30. FDA approval is anticipated in 2000. Eventually, Mosaic plans to extend the product line to include screening tests for donated red and white blood cells.
